Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Rhea-AI Summary

Immix Biopharma (NASDAQ: IMMX) will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA, November 10-12, 2025.

Management will participate in a Fireside Chat on November 11, 2025 at 12:30 PM ET and will be available for one-on-one meetings by request through Guggenheim representatives. A replay link will be posted on the company’s Investors > Presentation & Events page when available.

LOS ANGELES, CA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present and host institutional investor meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference being held November 10-12, 2025 in Boston, MA.

Management will participate in a Fireside Chat on Tuesday, November 11, 2025 at 12:30pm Eastern Time.

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Guggenheim representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NEXICART-2 primary endpoint was met at interim results presented at ASCO 2025. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.  

Forward Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Company Contact
irteam@immixbio.com

FAQ

When will Immix Biopharma (IMMX) present at the Guggenheim Healthcare Innovation Conference in 2025?

Immix Biopharma will present during the conference held November 10-12, 2025 in Boston, MA.

What time is the Immix Biopharma (IMMX) Fireside Chat at Guggenheim on November 11, 2025?

The Fireside Chat is scheduled for Tuesday, November 11, 2025 at 12:30 PM Eastern Time.

How can investors request one-on-one meetings with Immix Biopharma (IMMX) at the Guggenheim conference?

Interested investors should contact their Guggenheim representative to request one-on-one meetings.

Will a replay of the Immix Biopharma (IMMX) presentation be available after the Guggenheim conference?

Yes. A replay link will be posted to Immix Biopharma’s Investors > Presentation & Events page when available.

Where is the Guggenheim 2nd Annual Healthcare Innovation Conference being held for Immix Biopharma (IMMX)?

The conference is being held in Boston, Massachusetts from November 10-12, 2025.

Is Immix Biopharma (IMMX) hosting institutional investor meetings at the Guggenheim conference?

Yes. Management will host institutional investor meetings and is available for one-on-one sessions during the conference.